MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.

abstract：:The pharmacokinetics and metabolism of 4-demethoxydaunorubicin (idarubicin, IDA) were studied in 21 patients with advanced cancer after i.v. (12 mg/m2) and oral (30-35 mg/m2) treatment according to a balanced crossover design. Patients were divided into four groups: subjects who showed normal liver and kidney function...

journal_title：Cancer chemotherapy and pharmacology

authors： Camaggi CM,Strocchi E,Carisi P,Martoni A,Tononi A,Guaraldi M,Strolin-Benedetti M,Efthymiopoulos C,Pannuti F

更新日期：1992-01-01 00:00:00

abstract：:The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was no...

journal_title：Cancer chemotherapy and pharmacology

authors： Di Fronzo G,Bertuzzi A,Ronchi E,Villani FP,Ronchetti L

更新日期：1979-01-01 00:00:00

abstract：PURPOSE:Temozolomide (TMZ) is a widely used oral alkylating agent that has been associated with the development of severe hematologic adverse events (HAEs). Limited clinical information about HAEs is available. METHODS:We searched the FDA MedWatch database for TMZ and obtained all MedWatch reports on TMZ submitted to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Villano JL,Letarte N,Yu JM,Abdur S,Bressler LR

更新日期：2012-01-01 00:00:00

abstract：UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

更新日期：2002-05-01 00:00:00

abstract：PURPOSE:To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in a nonhuman primate model. METHODS:Tasidotin 0.75 mg/kg was administered intravenously. The plasma and CSF concentrations of tasidotin and its metabolites were determined. Pharmacokinetic pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Kilburn LB,Bonate PL,Blaney SM,McGuffey L,Nuchtern JG,Dauser R,Thompson P,Gibson BW,Berg SL

更新日期：2009-07-01 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：PURPOSE:The safety of S-1 in recurrent colorectal cancer patients with chronic myeloid leukemia (CML) treated with dasatinib has not been established. We evaluated the safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with CML treated with dasatinib. PATIENT:A 70-year-old man had undergone surgery...

journal_title：Cancer chemotherapy and pharmacology

authors： Sueda T,Kudo T,Sakai D,Uemura M,Nishimura J,Hata T,Takemasa I,Mizushima T,Yamamoto H,Ezoe S,Matsumoto K,Doki Y,Mori M,Satoh T

更新日期：2014-12-01 00:00:00

abstract：:Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

更新日期：2004-01-01 00:00:00

abstract：:The in vitro inhibitory action and metabolism of 1-beta-D-arabinofuranosylcytosine (ara-C) on human myeloid (HL-60), B-lymphoid (RPMI-8392), and T-lymphoid (Molt-3) leukemic cells was compared. Ara-C produced greater inhibitory effects in Molt-3 cells than in either HL-60 or RPMI-8392 cells. At a 48 h exposure, ara-C ...

journal_title：Cancer chemotherapy and pharmacology

authors： Momparler RL,Onetto-Pothier N,Bouffard DY,Momparler LF

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:To investigate the synergistic cytotoxicity of TRAIL in combination with chemotherapeutic agents in A549 cell lines, we systematically evaluated the cytotoxicity of TRAIL alone and TRAIL in combination with cisplatin, paclitaxel (Taxol) or actinomycin D in A549 cell lines in vitro and in vivo, and whether the s...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan QL,Zou WY,Song LH,Wei W

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS:Patients who failed prior standard therapy o...

journal_title：Cancer chemotherapy and pharmacology

authors： Holen KD,Belani CP,Wilding G,Ramalingam S,Volkman JL,Ramanathan RK,Vasist LS,Bowen CJ,Hodge JP,Dar MM,Ho PT

更新日期：2011-02-01 00:00:00

abstract：:We studied the release of histamine elicited by some antineoplastic drugs in rat pleural and peritoneal mast cells. The drugs tested included the antibiotic mitomycin; the anthracyclines daunorubicin, doxorubicin, and epirubicin; the glycopeptide bleomycin; the chromopeptide dactinomycin; the platinum coordination com...

journal_title：Cancer chemotherapy and pharmacology

authors： Botana LM,Arnaez E,Vieytes MR,Alfonso A,Louzao MC

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Differences in efficacy and toxicity between UDP-glucuronosyltransferase (UGT) 1A1*1/*1 and *1/*6 or *1/*28 genotypes remain unclear in Japanese patients. METHODS:Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were...

journal_title：Cancer chemotherapy and pharmacology

authors： Sunakawa Y,Ichikawa W,Fujita K,Nagashima F,Ishida H,Yamashita K,Mizuno K,Miwa K,Kawara K,Akiyama Y,Araki K,Yamamoto W,Miya T,Narabayashi M,Ando Y,Hirose T,Saji S,Sasaki Y

更新日期：2011-08-01 00:00:00

abstract：PURPOSE:Nephrotoxicity is one of the major dose-limiting side-effects of cisplatin (DDP). The disproportionate accumulation of cisplatin in kidney tissue may play an important role, however, therapeutic measures to prevent this prime cause of nephrotoxicity are not available. Because certain amino acids (AAs) have been...

journal_title：Cancer chemotherapy and pharmacology

authors： Kröning R,Lichtenstein AK,Nagami GT

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

journal_title：Cancer chemotherapy and pharmacology

authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

更新日期：2005-10-01 00:00:00

abstract：PURPOSE:Our previous studies have reported the antitumor effect of oleandrin on osteosarcoma; however, its chemosensitizing effect in osteosarcoma treatment is still unknown. Therefore, we explored the sensitizing effects of oleandrin to cisplatin in osteosarcoma and investigated the potential mechanisms. METHODS:Afte...

journal_title：Cancer chemotherapy and pharmacology

authors： Yong L,Ma Y,Zhu B,Liu X,Wang P,Liang C,He G,Zhao Z,Liu Z,Liu X

更新日期：2018-12-01 00:00:00

abstract：PURPOSE:To evaluate in vitro interactions of carboplatin, gemcitabine and paclitaxel in molecularly defined non-small-cell lung cancer lines. MATERIALS AND METHODS:Three NSCLC lines, A549 (p16-,p53 wt, Rb wt), Calu-1 (p16-, p53-, Rb+) and H596 (p16 wt, p53 mut, Rb-) were utilized. Cells were exposed to carboplatin, ge...

journal_title：Cancer chemotherapy and pharmacology

authors： Edelman MJ,Quam H,Mullins B

更新日期：2001-08-01 00:00:00

abstract：BACKGROUND AND PURPOSE:The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinom...

journal_title：Cancer chemotherapy and pharmacology

authors： Tanaka Y,Yoshida K,Sanada Y,Osada S,Yamaguchi K,Takahashi T

更新日期：2010-11-01 00:00:00

abstract：PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

更新日期：2013-03-01 00:00:00

abstract：:Comparative in vitro drug testing was performed in 72 of 183 surgically removed human colorectal cancer specimens (34 primary lesions, 38 metastases). In 10 of these tumors, comparative dose-response curves were obtained. Given a greater than or equal to 70% ICF (inhibition of colony formation) as threshold for in vit...

journal_title：Cancer chemotherapy and pharmacology

authors： Flentje M,Flentje D,Schlag P

更新日期：1986-01-01 00:00:00

abstract：:Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in ...

journal_title：Cancer chemotherapy and pharmacology

authors： Allan SG,Gregor A,Cornbleet MA,Leonard RC,Smyth JF,Grant IW,Crompton GK

更新日期：1984-01-01 00:00:00

abstract：:In January 1983, the German Society of Pediatric Oncology started a cooperative trial (MAKEI 83) for non-testicular germ-cell tumors. The pilot phase closed in December 1985. The treatment regimen was stratified according to histology, tumor site and tumor stage. In malignant non-seminomatous germ-cell tumors (mNSGCTs...

journal_title：Cancer chemotherapy and pharmacology

authors： Gobel U,Calaminus G,Häas RJ,Jurgens H,Niethammer D,Ritter J,Spaar HJ,Harms D

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND:Cancer has become one of the global health issues and it is the life-threatening disease characterized by unrestrained growth of cells. Despite various advances being adopted by chemotherapeutic management, the use of the current anticancer drugs such as Doxorubicin, Asparginase, Methotrexate, Vincristine re...

journal_title：Cancer chemotherapy and pharmacology

authors： Khanam R,Ahmad K,Hejazi II,Siddique IA,Kumar V,Bhat AR,Azam A,Athar F

更新日期：2017-11-01 00:00:00

abstract：PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS:Patients with advanced or recurrent untreated non-squamous NSCLC received ...

journal_title：Cancer chemotherapy and pharmacology

authors： Koba T,Minami S,Nishijima-Futami Y,Masuhiro K,Kimura H,Futami S,Yaga M,Mori M,Kagawa H,Uenami T,Kohmo S,Otsuka T,Yamamoto S,Komuta K,Kijima T

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:Many patients with non-small cell lung cancer (NSCLC) are eligible only for palliative radiation (RT) at presentation. This study was designed to assess the feasibility of adding the anti-EGFR monoclonal antibody nimotuzumab to palliative thoracic RT. METHODS:Patients with stage IIB, III or IV NSCLC considered...

journal_title：Cancer chemotherapy and pharmacology

authors： Bebb G,Smith C,Rorke S,Boland W,Nicacio L,Sukhoo R,Brade A

更新日期：2011-04-01 00:00:00

abstract：:Dihydroartemisinin, a more water-soluble metabolite of artemisinin derivatives, is a safe and most effective antimalarial analog of artemisinin. In the present study, we investigated the antiangiogenic activity of dihydroartemisinin in vitro and in vivo, and investigated dihydroartemisinin-induced apoptosis in human u...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen HH,Zhou HJ,Wang WQ,Wu GD

更新日期：2004-05-01 00:00:00

abstract：PURPOSE:P-glycoprotein is a 170-kDa plasma membrane multidrug transporter that actively exports cytotoxic substances from cells. Overexpression of P-glycoprotein by tumor cells is associated with a multidrug-resistant phenotype. Immunosuppressive agents such as cyclosporins and macrolides, have been shown to attenuate ...

journal_title：Cancer chemotherapy and pharmacology

authors： Mealey KL,Barhoumi R,Burghardt RC,McIntyre BS,Sylvester PW,Hosick HL,Kochevar DT

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:The ErbB family members are protein tyrosine kinases, which play a crucial role in the signal transduction pathways that regulate key cellular functions. Overexpression of the ErbB family members is associated with oncogenicity, metastatic potential, cell proliferation, apoptosis, angiogenesis, and prognosis in...

journal_title：Cancer chemotherapy and pharmacology

authors： Fu XH,Li J,Huang JJ,Zheng S,Zhang SZ

更新日期：2011-12-01 00:00:00

abstract：:In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tura S,Mazza P,Gherlinzoni F,Zinzani PL,Poletti G,Visani G,Lemoli RM,Cavo M,Galieni P,Tassi C

更新日期：1989-01-01 00:00:00